Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment
Credit Suisse has downgraded Editas Medicine Inc (NASDAQ: EDIT) from Outperform to Neutral with a price target of $13 from $25.
Thursday, Editas announced clinical data from the Phase 1/2 BRILLIANCE trial of EDIT-101, an in vivo CRISPR/Cas9 genome editing medicine.
Given the small population (around 300 in the U.S.), the company will pause enrollment in the BRILLIANCE trial and seek to identify a collaboration partner to continue the development of EDIT-101.
Credit Suisse says that Editas still maintains foundational intellectual property relating to CRISPR/Cas9 and CRISPR/Cas12a gene editing in human cells in relevant jurisdictions, which may lead to future licensing deals.
The company also plans to release Phase 1/2 RUBY data for EDIT-301 in sickle cell disease later this year. However, the data will be early, and interpretation could be limited.
With reasonably low expectations, Editas also maintains optionality with its preclinical oncology programs.
Opportunities for the stock are difficult to assess and be range bound in the near term.
Price Action: EDIT shares are down 2.41% at $10.75 on the last check Friday.
Latest Ratings for EDIT
Date | Firm | Action | From | To |
|---|---|---|---|---|
Feb 2022 | Oppenheimer | Maintains | Outperform | |
Feb 2022 | Chardan Capital | Maintains | Buy | |
Feb 2022 | SVB Leerink | Maintains | Market Perform |
View More Analyst Ratings for EDIT
View the Latest Analyst Ratings
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
